Adimmune

Focus: Adimmune is a Taiwan-based vaccine biotech founded in 2022, focusing on influenza and COVID-19 vaccine development across multiple platforms. The company is early-stage with a geographically concentrated presence in Taichung.

Infectious Diseases Vaccines

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About Adimmune

AI assessmentNot Hiring

No open roles listed right now. Follow Adimmune to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthStrong

Pipeline

Late-stage

5 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

A Pharmacovigilance Study for AdimFlu-S (A/H1N1) Influenza Vaccine in Pregnant Women

Adverse Drug Reactions

N/A

Clinical Trials (1)

NCT01354730A Pharmacovigilance Study for AdimFlu-S (A/H1N1) Influenza Vaccine in Pregnant Women

N/A

Help build intelligence for Adimmune

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Opportunity to work on Phase 3/4 influenza vaccine programs with established clinical trial data (9 trials for split virion inactivated formulation)
Exposure to pandemic preparedness vaccines including H5N1 and COVID-19 programs aligned with global health priorities
Ground-floor role at a newly founded (2022) vaccine biotech with potential for rapid advancement and equity upside

Watch Out For

Company is pre-revenue with no public funding data, cash runway, or financial transparency disclosed
Zero active job openings and minimal public information suggest either early stealth mode or limited hiring capacity

Generated by Claude from Adimmune's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

non-elderly aged between 18 and 60

Influenza

N/A

Clinical Trials (1)

NCT01411358Immunogenicity and Safety of AdimFlu-S 2011-2012 in Non-Elderly Adult and Elderly Subjects

N/A

Influenza A

Influenza

N/A

Clinical Trials (1)

NCT01007201Immunogenicity and Safety of Influenza Virus Vaccine, AdimFlu-S (A/H1N1), in Pediatric Population

N/A

Influenza A

Influenza

N/A

Clinical Trials (1)

NCT01003145Immunogenicity and Safety of Influenza Virus Vaccine, AdimFlu-S (A/H1N1), in Adults and Elders

N/A

AdimrSC-2f

COVID-19

Phase 1

Clinical Trials (1)

NCT04522089A Study to Evaluate the Safety and Immunogenicity of COVID-19 (AdimrSC-2f) Vaccine

Phase 1

COVID-19 vaccine (recombinant)

COVID-19

Phase 1/2

AdimrSC-2f

COVID-19

Phase 1/2

Clinical Trials (1)

NCT05104489Dose-finding Study for AdimrSC-2f Vaccine

Phase 1/2

Influenza vaccine (H5N1)

Pandemic Influenza

Phase 1/2

Clinical Trials (1)

NCT01640691Immunogenicity and Safety of Pandemic Influenza Vaccine in Healthy Adults

Phase 1/2

AdimFlu-V

Influenza

Phase 3

Clinical Trials (1)

NCT01755364A Trial to Assess the Immunogenicity and Safety of the Trivalent Virosomal Influenza Vaccine, Formulation of 2012-2013, in Healthy Subjects Aged Over 3 Years Old to 18 Years Old

Phase 3

AdimFlu-V

Influenza

Phase 3

Clinical Trials (1)

NCT01759654A Trial to Assess the Immunogenicity and Safety of the Trivalent Virosomal Influenza Vaccine, Formulation of 2012-2013, in Non-Elderly Adults and Elderly Subjects

Phase 3

Influenza vaccine (split virion, inactivated, QIS formulation)

Influenza

Phase 3

AdimFlu-S

Influenza

Phase 3

Clinical Trials (1)

NCT04101435Immunogenicity and Safety Evaluation of QIS in Healthy Subjects

Phase 3

Influenza vaccine (virosomal)

Influenza

Phase 3

AdimFlu-S

Influenza

Phase 4

Clinical Trials (1)

NCT01355172Immunogenicity and Safety of AdimFlu-S, Formulation 2010-2011, in Infants Aged Between 6-12months Old

Phase 4

AdimFlu-S Vaccine 2010-2011

Influenza

Phase 4

Clinical Trials (1)

NCT01356316Immunogenicity and Safety of a Trivalent Inactivated Influenza Vaccine, Formulation 2010-2011, in Non-Elderly Adult and Elderly Subjects

Phase 4

Influenza vaccine (split virion, inactivated)

Influenza

Phase 4

Clinical Trials (1)

NCT01752881Immunogenicity and Safety of a Trivalent Inactivated Influenza Vaccine, Formulation 2012-2013, in Non-Elderly Adult and Elderly Subjects

Phase 4

AdimFlu-S Influenza Vaccine

Influenza

Phase 4

Clinical Trials (1)

NCT01514708The Safety and Immune Response to Influenza Vaccination in Pregnant Women

Phase 4

AdimFlu-S 2010-2011, inactivated

Influenza

Phase 4

Clinical Trials (1)

NCT01356342Immunogenicity and Safety of a Trivalent Inactivated Influenza Vaccine, Formulation 2010-2011, in Healthy Subjects Aged Over 6 Months Old to 18 Years Old

Phase 4

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Founded: 2022

Portfolio: 15 clinical trials

Top TAs: Infectious Diseases

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Infectious Diseases

14 pipeline

Marketed

Pipeline